Clinical effects of blood donor characteristics in transfusion recipients: Protocol of a framework to study the blood donor-recipient continuum

BMJ Open

Volumn 5, Issue 1, 2015, Pages

  Chassé, Michaël ^a   McIntyre, Lauralyn ^a   Tinmouth, Alan ^a   Acker, Jason ^b   English, Shane W ^a,c   Knoll, Greg ^a   Forster, Alan ^d   Shehata, Nadine ^e   Wilson, Kumanan ^a,c,f   Van Walraven, Carl ^a   Ducharme, Robin ^a,f   Fergusson, Dean A ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD BANK; BLOOD DONOR; BLOOD SAFETY; BLOOD TRANSFUSION REACTION; CLINICAL PROTOCOL; COHORT ANALYSIS; DATA BASE; DONOR SELECTION; ERYTHROCYTE TRANSFUSION; HUMAN; IMMUNOMODULATION; LENGTH OF STAY; LONGITUDINAL STUDY; MEDICAL ETHICS; OUTCOME ASSESSMENT; RECIPIENT; RISK FACTOR; SENSITIVITY ANALYSIS; ADOLESCENT; ADULT; ADVERSE EFFECTS; AGE; CANADA; ERYTHROCYTE; FEMALE; HEMODIALYSIS; HISTOCOMPATIBILITY; HOSPITALIZATION; INFECTION; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; NEOPLASMS; SEX DIFFERENCE; SURVIVAL ANALYSIS; YOUNG ADULT;

BLOOD GROUP ANTIGEN;

ADOLESCENT; ADULT; AGE FACTORS; BLOOD DONORS; BLOOD GROUP ANTIGENS; CANADA; COHORT STUDIES; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; HISTOCOMPATIBILITY; HOSPITALIZATION; HUMANS; INFECTION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASMS; RENAL DIALYSIS; RESEARCH DESIGN; SEX FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84921872994     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-007412     Document Type: Article

References (49)

1. Canadian Blood Services 2012 Annual Report. Ottawa. 2012.
2. Rapport annuel 2012-2013 d'Héma-Québec. Québec. 2012.
3. Raghavan M, Marik PE. Anemia, allogenic blood transfusion, and immunomodulation in the critically ill. Chest 2005;127:295-307.
4. Bennett-Guerrero E, Zhao Y, O 'Brien SM, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA 2010;304:1568-75.
5. Amin M, Fergusson D, Wilson K, et al. The societal unit cost of allogenic red blood cells and red blood cell transfusion in Canada. Transfusion 2004;44:1479-86.
6. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409-17.
7. Hajjar LA, Vincent J-L, Galas FRBG, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA 2010;304:1559-67.
8. Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011;365:2453-62.
9. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 2008;36:2667-74.
10. Gilliss BM, Looney MR, Gropper MA. Reducing noninfectious risks of blood transfusion. Anesthesiology 2011;115:635-49.
11. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009;113:3406-17.
12. History of Blood Transfusion. Am Red Cross 2013. http://www.redcrossblood.org/learn-about-blood/history-blood-transfusion
13. O'Brien SF, Yi Q-L, Fan W, et al. Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services. Vox Sang 2012;103:83-6.
14. Jacobs JFM, Baumert JL, Brons PP, et al. Anaphylaxis from passive transfer of peanut allergen in a blood product. N Engl J Med 2011;364:1981-2.
15. Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012;119:1757-67.
16. Lin Y, Saw C-L, Hannach B, et al. Transfusion-related acute lung injury prevention measures and their impact at Canadian Blood Services. Transfusion 2012;52:567-74.
17. Chapman CE, Williamson LM. National Blood Service TRALI Reduction Policies: implementation and effect. Transfus Med Hemother 2008;35:93-6.
18. Murphy EL, Kwaan N, Looney MR, et al. Risk factors and outcomes in transfusion-associated circulatory overload. Am J Med 2013;126:357.e29-38.
19. Andrzejewski C, Casey MA, Popovsky MA. How we view and approach transfusion-associated circulatory overload: pathogenesis, diagnosis, management, mitigation, and prevention. Transfusion 2013;53:3037-47.
20. Lannan KL, Sahler J, Spinelli SL, et al. Transfusion immunomodulation - the case for leukoreduced and (perhaps) washed transfusions. Blood Cells Mol Dis 2013;50:61-8.
21. Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006;20:273-82.
22. Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-90.
23. Recipient Epidemiology and Donor Evaluation Study-III. Natl Heart Lung Blood Inst 2013. https://reds-iii.rti.org/ (accessed 9 Sep 2013).
24. Edgren G, Hjalgrim H. Epidemiological considerations for the use of databases in transfusion research: a Scandinavian perspective. Curr Opin Hematol 2010;17:596-601.
25. Edgren G, Hjalgrim H, Reilly M, et al. Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study. Lancet 2007;369:1724-30.
26. Edgren G, Kamper-Jørgensen M, Eloranta S, et al. Duration of red blood cell storage and survival of transfused patients (CME). Transfusion 2010;50:1185-95.
27. Edgren G, Hjalgrim H, Rostgaard K, et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol 2010;172:1280-5.
28. Borkent-Raven BA, Janssen MP, van der Poel CL, et al. The PROTON study: profiles of blood product transfusion recipients in the Netherlands. Vox Sang 2010;99:54-64.
29. Mission and Goals. Inst Clin Eval Sci. http://www.ices.on.ca/ (accessed 20 May 2013).
30. Donor Questionnaire. Can Blood Serv. http://www.blood.ca/ (accessed 20 May 2013).
31. Needham DM, Scales DC, Laupacis A, et al. A systematic review of the Charlson comorbidity index using Canadian administrative databases: a perspective on risk adjustment in critical care research. J Crit Care 2005;20:12-19.
32. Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004;57:1288-94.
33. Sharabiani MTA, Aylin P, Bottle A. Systematic review of comorbidity indices for administrative data. Med Care 2012;50:1109-18.
34. Van Walraven C, Bennett C, Forster AJ. Administrative database research infrequently used validated diagnostic or procedural codes. J Clin Epidemiol 2011;64:1054-9.
35. Van Walraven C, Austin P. Administrative database research has unique characteristics that can risk biased results. J Clin Epidemiol 2012;65:126-31.
36. Middelburg RA, le Cessie S, Briët E, et al. A solution to the problem of studying blood donor-related risk factors when patients have received multiple transfusions. Transfusion 2010;50:1959-66.
37. Eikelboom JW, Cook RJ, Liu Y, et al. Duration of red cell storage before transfusion and in-hospital mortality. Am Heart J 2010;159:737-43.e1.
38. Wong J, Taljaard M, Forster AJ, et al. Addition of time-dependent covariates to a survival model significantly improved predictions for daily risk of hospital death. J Eval Clin Pract 2013;19:351-7.
39. Forster AJ, Taljaard M, Oake N, et al. The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. CMAJ 2012;184:37-42.
40. Moher D, Pham B, Jones a, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609-13.
41. Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601-5.
42. Gwen C, Blajchman M. Clinical Guide to Transfusion. Toronto, Canada: Canadian Blood Services, 2007:1-182.
43. Hess JR, Greenwalt TG. Storage of red blood cells: new approaches. Transfus Med Rev 2002;16:283-95.
44. Lelubre C, Piagnerelli M, Vincent J-L. Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality? Transfusion 2009;49:1384-94.
45. Tinmouth A, Fergusson D, Yee IC, et al. Clinical consequences of red cell storage in the critically ill. Transfusion 2006;46:2014-27.
46. Vamvakas EC. Meta-analysis of clinical studies of the purported deleterious effects of "old" (versus "fresh") red blood cells: are we at equipoise? Transfusion 2010;50:600-10.
47. Triulzi DJ, Yazer MH. Clinical studies of the effect of blood storage on patient outcomes. Transfus Apher Sci 2010;43:95-106.
48. Fergusson DA, Hébert P, Hogan DL, et al. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. JAMA 2012;308:1443-51.
49. Aubron C, Nichol A, Cooper DJ, et al. Age of red blood cells and transfusion in critically ill patients. Ann Intensive Care 2013;3:2.